|Bid||1.6000 x 2200|
|Ask||1.6300 x 1800|
|Day's Range||1.6000 - 1.7100|
|52 Week Range||1.6000 - 18.9000|
|Beta (5Y Monthly)||0.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.83|
Fresh Tracks Therapeutics ( NASDAQ:FRTX ) Third Quarter 2022 Results Key Financial Results Revenue: US$486.0k (up 268...
Fresh Tracks Therapeutics (FRTX) delivered earnings and revenue surprises of -9.52% and 56.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Phase 1 study of FRTX-02 progressing well, with the SAD portion complete and MAD portion underway Remain on track to report SAD and MAD topline results from the Phase 1 study of FRTX-02 by early 2023 Advancing the development of FRTX-10 through early preclinical stage studies BOULDER, Colo., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing i